ReviewIndian journal of anaesthesia2025
Care of the immunocompromised cancer patient in the perioperative period: Narrative review.
Review in Indian journal of anaesthesia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cancer is emerging as a significant global public health concern. Worldwide, the incidence of cancer is predicted to increase by 50% by the year 2030. Over 80% of patients will need anaesthetic care and services for perioperative and periprocedural care, as well as for other non-cancer-related procedures. It is estimated that by 2030, over 45 million surgical procedures will be needed globally for cancer control alone. Immunosuppressed patients with cancer represent a unique subset of the population who are at a heightened risk of developing severe infections due to neutropenia, lymphopenia, and immune impairment. The complex nature of the deranged immunologic profiles, compounded by using immune-altering therapies (e.g. corticosteroids, cytotoxic drugs, and immunotherapy) during the perioperative period and after the index surgical procedure, increases the risk of various complications and unfavourable cancer-related outcomes. Therefore, understanding and addressing the unique needs of cancer patients with immune compromise is crucial for improving their prognosis and overall survival rates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.